Drugs / ENVUCITINIB
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06952634 | Apr 2025 → Mar 2026 | — | Alumis Inc | Completed | No outcome recorded |
| Phase 1 | NCT06962774 | Apr → Aug 2025 | impaired renal function disease | Alumis Inc | Completed | No outcome recorded |
| Phase 1 | NCT07378579 | Jun → Aug 2024 | — | Alumis Inc | Completed | No outcome recorded |
| Phase 1 | NCT05431634 | May → Dec 2022 | — | Alumis Inc | Completed | No outcome recorded |
| Phase 1 | NCT05330858 | Mar → Jun 2022 | — | Alumis Inc | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05966480 | Jun 2023 → Jul 2026 overdue | systemic lupus erythematosus | Alumis Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05953688 | Jun 2023 → Aug 2024 | intermediate uveitis, panuveitis, posterior uveitis | Alumis Inc | Terminated | No outcome recorded |
| Phase 2 | NCT05739435 | Jan 2023 → Dec 2026 expected | psoriasis | Alumis Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05600036 | Sep 2022 → Jun 2023 | psoriasis | Alumis Inc | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06846541 | Jan 2025 → Nov 2028 expected | psoriasis | Alumis Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06588738 | Aug 2024 → Sep 2025 | psoriasis | Alumis Inc | Completed | No outcome recorded |
| Phase 3 | NCT06586112 | Jul 2024 → Sep 2025 | psoriasis | Alumis Inc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENVUCITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5499275 ↗ |
| Known as | Envudeucitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06586112 ↗ |
| Known as | ESK-001 | “Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily...” NCT06846541 ↗7“Envudeucitinib (ESK-001), a highly selective, oral tyrosine kinase 2 inhibitor” PMID 41061968 ↗ Oct 2025 |
| Action | Inhibit | “Highly selective, allosteric inhibition of TYK2 with oral ESK-001” PMID 40659116 ↗ Jul 2025 |
| Modality | Small molecule | — CHEMBL5499275 ↗ |
| Route | Oral | “ESK-001 administered as an oral liquid” NCT05330858 ↗ |
| Target | TYK2 | “Highly selective, allosteric inhibition of TYK2 with oral ESK-001” PMID 40659116 ↗ Jul 2025 |